Free Trial

Emergent Biosolutions (EBS) Competitors

Emergent Biosolutions logo
$7.32 -0.01 (-0.16%)
As of 03:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EBS vs. JNJ, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, RGLS, and MYGN

Should you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), and Myriad Genetics (MYGN). These companies are all part of the "medical" sector.

Emergent Biosolutions vs. Its Competitors

Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent Biosolutions$1.04B0.38-$190.60M-$2.71-2.71
Johnson & Johnson$88.82B4.27$14.07B$8.9917.54

Johnson & Johnson has a net margin of 24.42% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.46% beat Emergent Biosolutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Emergent Biosolutions-13.63% -0.52% -0.17%
Johnson & Johnson 24.42%33.46%13.30%

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Johnson & Johnson had 108 more articles in the media than Emergent Biosolutions. MarketBeat recorded 114 mentions for Johnson & Johnson and 6 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.33 beat Emergent Biosolutions' score of 0.52 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Emergent Biosolutions
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Johnson & Johnson
97 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Emergent Biosolutions has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Emergent Biosolutions currently has a consensus price target of $14.33, indicating a potential upside of 94.85%. Johnson & Johnson has a consensus price target of $171.00, indicating a potential upside of 8.43%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, research analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emergent Biosolutions
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Johnson & Johnson
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.55

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EBS vs. The Competition

MetricEmergent BiosolutionsMED IndustryMedical SectorNYSE Exchange
Market Cap$400.42M$2.96B$5.58B$20.58B
Dividend YieldN/A2.44%5.25%3.74%
P/E Ratio-2.7221.4727.5128.09
Price / Sales0.38259.84415.8441.25
Price / Cash3.5841.8337.0622.25
Price / Book0.837.788.084.61
Net Income-$190.60M-$55.05M$3.17B$982.91M
7 Day Performance5.24%5.38%3.57%3.27%
1 Month Performance9.22%3.87%3.74%4.39%
1 Year Performance-20.82%5.72%33.78%15.00%

Emergent Biosolutions Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EBS
Emergent Biosolutions
4.2911 of 5 stars
$7.32
-0.2%
$14.33
+95.9%
-16.6%$396.52M$1.04B-2.702,420News Coverage
JNJ
Johnson & Johnson
4.8775 of 5 stars
$155.23
-0.5%
$170.88
+10.1%
+6.1%$373.49B$88.82B17.27138,100Trending News
Upcoming Earnings
Analyst Forecast
CLDX
Celldex Therapeutics
3.0795 of 5 stars
$20.98
-4.6%
$50.11
+138.9%
-39.6%$1.39B$7.56M-7.77150Analyst Forecast
DVAX
Dynavax Technologies
4.3683 of 5 stars
$10.30
+0.3%
$24.00
+133.0%
-1.5%$1.24B$277.25M-19.81350
INVA
Innoviva
4.3074 of 5 stars
$18.91
-1.6%
$55.00
+190.9%
+15.5%$1.19B$369.84M-18.72100
MNKD
MannKind
2.5333 of 5 stars
$3.54
-1.7%
$10.33
+191.9%
-28.6%$1.08B$285.50M35.40400Negative News
NVAX
Novavax
4.4824 of 5 stars
$6.61
-2.8%
$17.00
+157.2%
-40.5%$1.07B$682.16M2.491,990
OPK
OPKO Health
4.6403 of 5 stars
$1.34
-1.5%
$2.75
+105.2%
+7.0%$1.06B$713.10M-19.142,997News Coverage
Analyst Upgrade
GERN
Geron
2.7866 of 5 stars
$1.37
-4.2%
$5.06
+269.5%
-68.6%$872.58M$76.99M-6.5270News Coverage
Analyst Forecast
RGLS
Regulus Therapeutics
1.5879 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
MYGN
Myriad Genetics
4.1589 of 5 stars
$5.29
-5.5%
$14.38
+171.9%
-77.3%$487.63M$837.60M-4.722,700News Coverage

Related Companies and Tools


This page (NYSE:EBS) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners